(Q36980742)

17 August 2017

1 reference

title

The scavenger receptor BI and its ligand, HDL: partners in crime against HCV neutralizing antibodies (English)

1 reference

17 August 2017

Dreux M

1

1 reference

PubMed ID

17958646

17 August 2017

Cosset FL

series ordinal

2

1 reference

17 August 2017

1 November 2007

1 reference

Journal of Viral Hepatitis

17 August 2017

1 reference

17 August 2017

14 Suppl 1

1 reference

17 August 2017

68-76

1 reference

Hepatitis C virus genetic variability: pathogenic and clinical implications

17 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Determinants of viral clearance and persistence during acute hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Analysis of a successful immune response against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Hepatitis C virus infection: when silence is deception.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Complete replication of hepatitis C virus in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Robust hepatitis C virus infection in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Neutralizing antibody response during acute and chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Effect of immune globulin on the prevention of experimental hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Long-term persistence of hepatitis C virus antibodies in a single source outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Hepatitis C virus variability: sequence analysis of an isolate after 10 years of chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Association of hepatitis C virus in human sera with beta-lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Reduction of hepatitis C virus load by H.E.L.P.-LDL apheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Binding of human lipoproteins (low, very low, high density lipoproteins) to recombinant envelope proteins of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Density analysis of hepatitis C virus particle population in the circulation of infected hosts: implications for virus neutralization or persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Enhancing antibodies in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

A physical and functional link between cholesterol and tetraspanins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Conservation of the Conformation and Positive Charges of Hepatitis C Virus E2 Envelope Glycoprotein Hypervariable Region 1 Points to a Role in Cell Attachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Structural basis of T cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Antibodies, viruses and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Preclinical Evaluation of Two Neutralizing Human Monoclonal Antibodies against Hepatitis C Virus (HCV): a Potential Treatment To Prevent HCV Reinfection in Liver Transplant Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00919.X

10.1111/J.1365-2893.2007.00919.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17958646